Elanco (ELAN)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$24.50+0.33%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ELAN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | 5,020.0 | 4,715.0 | 4,439.0 | 4,417.0 | 4,411.0 | 4,764.0 | 3,273.0 | 3,071.0 | 3,066.8 |
| Cost of Revenues | 2,241.0 | 2,122.0 | 2,003.0 | 1,931.0 | 1,913.0 | 2,132.0 | 1,667.0 | 1,470.0 | 1,573.8 |
| Gross Profit | 2,779.0 | 2,593.0 | — | 2,486.0 | — | — | — | — | — |
| Operating Expenses & Income | |||||||||
| Selling, General & Admin | 1,519.0 | 1,430.0 | 1,314.0 | 1,285.0 | 1,265.0 | 1,403.0 | 997.0 | 760.0 | 735.2 |
| R&D Expenses | 371.0 | 368.0 | 344.0 | 327.0 | 321.0 | 369.0 | 329.0 | 270.0 | 246.6 |
| Other Operating Expenses, Total | — | (19.0) | (18.0) | (75.0) | (32.0) | — | — | — | — |
| Operating Income | — | — | — | (1,195.0) | (72.0) | (571.0) | (677.0) | 78.0 | 114.1 |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | — | — | 277.0 | 241.0 | 236.0 | 150.0 | 79.0 | 29.6 |
| Interest & Investment Income | — | 43.0 | 31.0 | 4.0 | — | — | — | — | — |
| Net Interest Expenses | — | — | — | 273.0 | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | — | — | (75.0) | (32.0) | (5.0) | 178.0 | (28.0) | (41.3) |
| Asset Writedown | — | 71.0 | — | 32.0 | — | 66.0 | 17.0 | 16.0 | 81.9 |
| EBT, Incl. Unusual Items | (166.0) | (224.0) | 488.0 | (1,195.0) | (72.0) | (571.0) | (677.0) | 78.0 | 114.1 |
| Income Tax Expense | 33.0 | 8.0 | 150.0 | 36.0 | 6.0 | (88.0) | (103.0) | 10.0 | 27.6 |
| Net Income | |||||||||
| Net Income | (199.0) | (232.0) | 338.0 | (1,231.0) | (78.0) | (483.0) | (574.0) | 68.0 | 86.5 |
| Per Share | |||||||||
| Basic EPS | (0.40) | (0.47) | 0.68 | (2.50) | (0.16) | (0.99) | (1.30) | 0.18 | — |
| Diluted EPS | (0.39) | (0.47) | 0.68 | (2.50) | (0.16) | (0.99) | (1.30) | 0.18 | — |
| Revenue per Share | 9.92 | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 499.5 | 496.4 | 494.0 | 492.3 | 488.3 | 487.2 | 441.4 | 369.0 | 293.3 |
| Diluted Weighted Avg Shares | 505.9 | 496.4 | 497.3 | 492.3 | 488.3 | 487.2 | 441.4 | 370.3 | — |
| Supplemental | |||||||||
| EBITDA | — | — | — | (501.0) | 610.0 | 145.0 | (160.0) | 392.0 | 410.1 |
| EBIT | — | — | — | (1,195.0) | (72.0) | (571.0) | (677.0) | 78.0 | 114.1 |
| Effective Tax Rate | -19.9% | — | — | -3.0% | -8.3% | 15.4% | 15.2% | 12.8% | 24.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.